Search clinical trials for: erlotinib [Tarceva]

Total 1401 results

Memorial Sloan Kettering Cancer Center

Completed

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Oligometastatic Lung Adenocarcinoma

United States
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (ELEMENT)

Non-Squamous Non-Small Cell Lung Cancer

Serbia
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Lung Adenocarcinoma | Minimally Invasive Lung Adenocarcinoma | Malignant Pleural Effusion | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Malignant Pericardial Effusion | Lung Adenosquamous Carcinoma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Eli Lilly and Company

Active, not recruiting

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (Balise)

Carcinoma, Non-Small-Cell Lung

Spain, Taiwan, United Kingdom, France, Germany, Netherlands, Korea, Republic of, Italy, Denmark
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Completed

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Lung Cancer

United States
The Cleveland Clinic

Unknown

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Exelixis

Completed

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital; Korean Cancer Study Group

Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Leptomeningeal Carcinomatosis

Korea, Republic of
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
XSpray Microparticles

Completed

Pharmacokinetic Comparison of XS003 and Tasigna

Healthy

United Kingdom
The Methodist Hospital Research Institute
Schering-Plough

Terminated

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Carcinoma, Renal Cell

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
NCIC Clinical Trials Group
Roche Pharma AG

Completed

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

Canada
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Alaunos Therapeutics

Unknown

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Advanced Solid Tumors

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Non-small-cell Lung Cancer

Japan
University of Aarhus
Aarhus University Hospital

Terminated

Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC

Lung Cancer

Denmark
Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Stage IV Ovarian Epithelial Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma... and other conditions

United States
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Spain, Belgium, France, United Kingdom, Netherlands, Italy, Israel, Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Wu Jieping Medical Foundation
Zhejiang Cancer Hospital; Fudan University; Shanghai Chest Hospital; Shanghai Pulmonary... and other collaborators

Unknown

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment (ROLE)

Non Small Cell Lung Cancer, Oligometastatic

China
Zhejiang Cancer Hospital

Unknown

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0901)

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Genentech, Inc.

Completed

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Breast Cancer
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Glioblastoma
Agennix

Completed

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Lung Cancer

United States, Canada, Chile
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Advanced Solid Tumors

Germany, Czechia, United States, Brazil, Poland, Singapore, Thailand
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Sarcoma

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
AZ-VUB
Hoffmann-La Roche

Unknown

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Lung Neoplasms | Non-Small Cell Lung Cancer | Adenocarcinoma, Bronchiolo-Alveolar

Belgium
Massachusetts Institute of Technology
Massachusetts General Hospital

Not yet recruiting

Investigating the Effects of Cannabidiol on Social Anxiety Disorder (CAN-SAD)

Phobia, Social

United States
Patrick Joseph Loehrer Sr.
Exelixis

Terminated

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Metastatic

United States
University of Michigan Rogel Cancer Center
Augusta University

Withdrawn

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Non-Small Cell Lung Cancer

United States
Pfizer

Completed

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Non-Small Cell Lung Cancer

United States
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease

Search clinical trials for: erlotinib [Tarceva]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations